title: Association of endostatin with mortality in patients with chronic heart failure.
abstract: BACKGROUND
  Experimental data imply that in decompensated heart failure (HF), the anti-angiogenic factor endostatin is increased. This study aimed to investigate whether the angiogenesis inhibitor endostatin is related to the risk of all-cause mortality in a prospective cohort study of chronic HF patients.
  
  
  METHODS
  In this prospective observational cohort study, endostatin serum concentrations were determined in patients with chronic HF. Mortality data were recorded during a median follow-up of 31 months.
  
  
  RESULTS
  One fifty one patients were included. The overall mortality rate was 20%. Baseline endostatin concentrations > 245 ng/mL were associated with higher risk of all-cause mortality [HR 8·7 (95% CI 2·5-30·0); P = 0·001] in the multivariate analysis as compared to endostatin concentrations ≤ 245 ng/mL. When both endostatin and NT-proBNP were above the calculated cut-off of 245 ng/mL and 2386 pg/mL, respectively, the prognostic utility of both biomarkers increased [HR 40·8 (95% CI 4·7-354·6); P = 0·001] compared with values lower than the cut-offs.
  
  
  CONCLUSIONS
  Serum endostatin concentrations are independently associated with all-cause mortality. Furthermore, combination of endostatin and NT-proBNP discriminates patients at high risk.
authors.affiliation: Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria.
authors.forename: Ghazaleh
authors.initials: G
authors.lastname: Gouya
authors.forename: Jolanta M
authors.initials: JM
authors.lastname: Siller-Matula
authors.forename: Monika
authors.initials: M
authors.lastname: Fritzer-Szekeres
authors.forename: Stephanie
authors.initials: S
authors.lastname: Neuhold
authors.forename: Angela
authors.initials: A
authors.lastname: Storka
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Neuhofer
authors.forename: Martin
authors.initials: M
authors.lastname: Clodi
authors.forename: Martin
authors.initials: M
authors.lastname: Hülsmann
authors.forename: Richard
authors.initials: R
authors.lastname: Pacher
authors.forename: Michael
authors.initials: M
authors.lastname: Wolzt
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000378:metabolism; D002908:Chronic Disease; D043169:Endostatins / Q000378:metabolism*; D004812:Epidemiologic Methods; D005260:Female; D006333:Heart Failure / Q000401:mortality*; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D045283:Natriuretic Agents / Q000494:pharmacology; D020097:Natriuretic Peptide, Brain / Q000378:metabolism / Q000494:pharmacology; D010446:Peptide Fragments / Q000378:metabolism; D011379:Prognosis; D055815:Young Adult
chemical_list: D015415:Biomarkers; D043169:Endostatins; D045283:Natriuretic Agents; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain
keywords: All-cause mortality; endostatin; heart failure